CV Risk Stratification Decision Factors

First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.

Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.

Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.

An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.

Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.

The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.